IQVIA Holdings (IQV) shares rallied 3% in the last trading session to close at $197.27. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 3.1% loss over the past four weeks.The stock has recorded the price rise as the company’s short-cycle businesses continue to improve on the back of its clients’ launching drugs and executing critical commercial programs.This clinical testing company is expected to post quarte ...

Join Compounding Healthcare where we employ data analytics in combination with technical analysis and clinical data breakdown in order to manage a position in numerous potential multi-bagger investments that can grow into a comprehensive healthcare portfolio.It has been roughly 10 months from my previous article on IQVIA Holdings (NYSE: IQV ), where I discussed the company's Q4 2023 marks, which beat the Street's expectations thanks to record revenues and EPS growth. At that time, IQVIA publicizedHe is the ...

While IQVIA Holdings Inc. (IQV) benefits from its market leadership, data-driven innovation, and global expansion, it must navigate pricing pressure.IQV has an expected long-term (three to five years) EPS growth rate of 9.6%. The company’s earnings for 2024 and 2025 are expected to grow 9% and 6.9%, respectively.IQV’s Global Reach, Market Leadership in Healthcare AnalyticsIQVIA operates in over 100 countries, giving it a vast global footprint. This extensive presence enables it to tap into emerging markets ...

For the quarter ended September 2024, IQVIA Holdings (IQV) reported revenue of $3.9 billion, up 4.3% over the same period last year. EPS came in at $2.84, compared to $2.49 in the year-ago quarter.The reported revenue represents a surprise of +1.11% over the Zacks Consensus Estimate of $3.85 billion. With the consensus EPS estimate being $2.81, the EPS surprise was +1.07%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street e ...

Revenue Growth - For Q3 2024, total revenues increased by $160 million, or 4.3%, to $3,896 million compared to Q3 2023, driven by a $118 million increase in Technology & Analytics Solutions[95]. - For the first nine months of 2024, total revenues rose by $331 million, or 3.0%, to $11,447 million, with constant currency growth of approximately $393 million, or 3.5%[96]. - For the three months ended September 30, 2024, total revenues increased to $3,896 million, up 4.3% from $3,736 million in the same period of 2023[110]. - Technology & Analytics Solutions reported revenues of $1,554 million for Q3 2024, an increase of $123 million, or 8.6%, compared to Q3 2023[114]. - Research & Development Solutions' revenues for the third quarter of 2024 were $2,162 million, reflecting an increase of $40 million, or 1.9%, over the same period in 2023[125]. - Revenues for Contract Sales & Medical Solutions were $541 million for the first nine months of 2024, consistent with the same period in 2023, with constant currency revenue growth of approximately $16 million, or 3.0%[136]. Cost and Expenses - Cost of revenues for Q3 2024 increased by $92 million, or 3.8%, to $2,518 million, with a constant currency increase of approximately $156 million, or 6.4%[97]. - The company reported a $183 million increase in cost of revenues for the first nine months of 2024, with a constant currency increase of approximately $480 million, or 6.6%[98]. - Selling, general and administrative expenses for Q3 2024 rose by $20 million, or 4.0%, to $522 million, maintaining a consistent percentage of revenues at 13.4%[99]. - Selling, general and administrative expenses for Technology & Analytics Solutions increased by $10 million, or 4.6%, in Q3 2024 compared to Q3 2023[120]. - The cost of revenues for Technology & Analytics Solutions increased by $63 million, or 7.3%, in Q3 2024 over the same period in 2023[117]. - Research & Development Solutions' cost of revenues increased by $32 million, or 2.3%, in Q3 2024 compared to Q3 2023[128]. - Cost of revenues, exclusive of depreciation and amortization, increased by $1 million, or 0.2%, in the first nine months of 2024 compared to the same period in 2023, with a constant currency increase of approximately $15 million, or 3.3%[138]. - Selling, general and administrative expenses increased by $2 million, or 4.7%, in the first nine months of 2024 compared to the same period in 2023[139]. Financial Performance - The effective income tax rate for Q3 2024 was 18.6%, compared to 14.6% in Q3 2023, influenced by changes in geographical earnings mix[108]. - Other expense (income), net for the nine months ended September 30, 2024, decreased primarily due to foreign currency loss on transactions[106]. - Net revenues for the nine months ended September 30, 2024, were $4,979 million, down from $6,299 million for the twelve months ended December 31, 2023, representing a decrease of 20.9%[161]. - Costs and expenses applicable to net revenues decreased from $4,190 million to $3,120 million, a reduction of 25.6%[161]. - Net income increased significantly from $86 million for the twelve months ended December 31, 2023, to $237 million for the nine months ended September 30, 2024, an increase of 175.6%[161]. Cash Flow and Financing - Cash provided by operating activities increased by $429 million during the first nine months of 2024, totaling $1,831 million compared to $1,402 million in the same period in 2023[149]. - Net cash used in investing activities decreased by $257 million during the first nine months of 2024, totaling $(1,134) million compared to $(1,391) million in the same period in 2023[150]. - Net cash used in financing activities increased by $541 million during the first nine months of 2024, totaling $(503) million compared to $38 million in the same period in 2023[152]. - As of September 30, 2024, the company had a cash balance of $1,572 million, an increase from $1,376 million as of December 31, 2023[142]. - Total stock repurchase authorization under the equity repurchase program was $11,725 million as of September 30, 2024, with remaining authorization to repurchase up to $2,163 million[144][145]. - Total indebtedness as of September 30, 2024, was $13,578 million, excluding $1,995 million of additional available borrowings under the revolving credit facility[146]. - The company completed the issuance of $1,250 million in gross proceeds of senior secured notes due 2029 and $750 million in gross proceeds of senior secured notes due 2028 in 2023[153][154]. Operational Insights - The company has approximately 88,000 employees across over 100 countries, focusing on accelerating the development and commercialization of innovative medical treatments[88]. - The company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions, each contributing to revenue growth[90]. - The contracted backlog for Research & Development Solutions increased from $29.7 billion as of December 31, 2023, to $31.1 billion as of September 30, 2024[124]. Balance Sheet Changes - Total current assets decreased from $805 million as of December 31, 2023, to $756 million as of September 30, 2024, a decline of 6.1%[160]. - Total current liabilities increased from $3,471 million to $4,047 million, an increase of 16.6%[160]. - Total noncurrent liabilities decreased from $12,334 million to $11,611 million, a reduction of 5.9%[160]. - Amounts due from subsidiaries that are non-Guarantors decreased from $4,762 million to $4,390 million, a decline of 7.8%[160]. - Amounts due to subsidiaries that are non-Guarantors increased from $5,556 million to $6,131 million, an increase of 10.3%[160]. Regulatory and Accounting Updates - The company does not expect any material impacts from the OECD's Pillar 2 global corporate minimum tax rate of 15% for 2024[109]. - There have been no material changes to critical accounting policies as previously disclosed in the 2023 Form 10-K[165]. - There have been no material changes to market risk disclosures compared to the 2023 Form 10-K[166].

Financial Data and Key Metrics - Revenue for Q3 2024 grew 4.3% on a reported basis and 4.2% at constant currency, with COVID-related revenues at $20 million, down from $100 million in Q3 2023 [34] - Adjusted EBITDA increased 5.7% in Q3, driven by revenue growth and cost management, resulting in 30 bps of margin expansion [20] - Adjusted diluted EPS for Q3 was $2.84, up 14.1% year-over-year [20] - Backlog reached a record $31.1 billion, up 8% year-over-year, with next 12 months revenue from backlog up 5.5% [17][38] - Free cash flow for Q3 was $571 million, with $200 million spent on share repurchases [40] Business Line Performance - Technology & Analytics Solutions (TAS) revenue grew 8.6% reported and 8.2% at constant currency, with organic growth in mid-single-digits [35][68] - R&D Solutions (R&DS) revenue grew 1.9% reported and 2% at constant currency, with 6% growth excluding COVID-related work [35] - Contract Sales and Medical Solutions (CSMS) revenue declined 1.6% reported and 1.1% at constant currency [35] Market Performance - Biotech funding reached $16 billion in Q3, with year-to-date funding over $80 billion, representing more than 50% growth year-over-year [16] - RFP flow increased mid-single digits year-over-year, with qualified pipeline growing low double-digits overall [17][18] Strategic Direction and Industry Competition - The company successfully renewed all large pharma strategic partnerships and expanded relationships with over half a dozen clients [14][15] - The launch of IQVIA AI Assistant, a generative AI tool, aims to provide life science customers with real-time insights [27][28] - The company continues to differentiate in oncology, with several leading sponsors selecting IQVIA for global Phase III studies [23][24] Management Commentary on Operating Environment and Future Outlook - The near-term market environment for clinical trials remains choppy, with aggressive competitive pricing and higher-than-normal cancellations due to the IRA [11] - The company expects TAS to grow approximately 6% and R&DS to grow 5% for the full year, both at constant currency and excluding COVID-related impacts [43] - Management anticipates mid-single-digit growth for 2025, with TAS expected to grow around 6% and R&DS around 5% [50][51] Other Important Information - The company updated its full-year guidance due to delays in two mega trials, now expecting revenue between $15.350 billion and $15.400 billion, adjusted EBITDA between $3.675 billion and $3.7 billion, and adjusted diluted EPS between $11.10 and $11.20 [42] - The company plans to provide preliminary 2025 guidance at its Investor Day on December 10th [48] Q&A Summary Question: Thoughts on preliminary 2025 growth expectations? - The company expects mid-single-digit growth for 2025, with TAS growing around 6% and R&DS around 5% [50][51] Question: Details on trial delays and confidence in resumption? - The delays are due to client-related logistical issues, unrelated to financials or drug futility, and the trials are expected to resume in 2025 [55][56][60] Question: Timing and impact of cancellations on 2025? - Cancellations are split between reprioritization and drug futility, with reprioritization expected to peak by the end of 2024 [61][62] - Delays in trials will affect sequential growth but are not expected to be incremental to 2025 [65][66] Question: M&A strategy and financial profile? - The company spent $649 million on acquisitions year-to-date, with a focus on small deals, and expects to continue deploying capital for acquisitions and share repurchases [68][69][75] Question: Pricing pressure and cost management? - Pricing pressure is tough across the board, particularly in FSP, and the company is managing costs while navigating delays and cancellations [81][82][91] Question: Strategic partnerships and interest expense? - The company has largely completed strategic partnership renewals and expects interest expense for 2024 to be around $625 million [94][96] Question: Conditions for R&DS growth in 2025? - Growth expectations for R&DS in 2025 are based on the resumption of delayed trials and the end of program reprioritizations [101][102]

IQVIA Holdings Analytics Inc. (IQV) has reported impressive third-quarter 2024 results, wherein earnings and revenues beat the Zacks Consensus Estimate.See Zacks Earnings Calendar to stay ahead of market-making news.Adjusted earnings were $2.8 per share, outpacing the Zacks Consensus Estimate by 1.1% and rising 14.1% on a year-over-year basis. Total revenues of $3.9 billion surpassed the consensus estimate by 1.1% and grew 4.3% from the year-ago quarter.The IQV stock has gained 20% over the past year, under ...

IQVIA Holdings (IQV) came out with quarterly earnings of $2.84 per share, beating the Zacks Consensus Estimate of $2.81 per share. This compares to earnings of $2.49 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.07%. A quarter ago, it was expected that this clinical testing company would post earnings of $2.58 per share when it actually produced earnings of $2.64, delivering a surprise of 2.33%.Over the last four quarters, ...

Exhibit 99.1 IQVIA Reports Third-Quarter 2024 Results and Announces Investor Day • Revenue of $3,896 million • GAAP Net Income of $285 million, Adjusted EBITDA of $939 million • GAAP Diluted Earnings per Share of $1.55, Adjusted Diluted Earnings per Share of $2.84 • R&D Solutions quarterly bookings of $2.3 billion, resulting in trailing-twelve-month bookings of $10.4 billion and a trailing-twelve-month book-to-bill ratio of 1.22x • R&D Solutions contracted backlog of $31.1 billion, up 8.0 percent reported y ...

IQVIA Holdings, Inc. (IQV) is scheduled to release its third-quarter 2024 results on Oct. 31, before market open. See Zacks Earnings Calendar to stay ahead of market-making news. IQV has an impressive earnings surprise history, having surpassed the Zacks Consensus Estimate in the trailing four quarters, the average surprise being 1.8%. IQVIA's Q3 Expectations The Zacks Consensus Estimate for revenues is pegged at $3.9 billion, implying 3.1% growth from the year-ago quarter's actual. The top line is likely t ...